IP Library Granted Patent US 9,025,727
Granted Patent B2
US 9,025,727 · App. 13/949,063 · Granted May 5, 2015

Methods and devices for orthovoltage ocular radiotherapy and treatment planning

Inventors: Michael Gertner (Menlo Park, CA); Mark Arnoldussen (San Carlos, CA); Erik Chell (Oakland, CA); Steven D. Hansen (Concord, CA); Junzhong Liang (Fremont, CA)
Assignee: Oraya Therapeutics, Inc.
A61N5/1037A61N5/1017A61N5/103A61N5/1064A61N2005/1091
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,025,727
App. No.
13/949,063
Granted
May 5, 2015
Kind
B2
Abstract

A method, code and system for planning the treatment a lesion on or adjacent to the retina of an eye of a patient are disclosed. There is first established at least two beam paths along which x-radiation is to be directed at the retinal lesion. Based on the known spectral and intensity characteristics of the beam, a total treatment time for irradiation along each beam paths is determined. From the coordinates of the optic nerve in the aligned eye position, there is determined the extent and duration of eye movement away from the aligned patient-eye position in a direction that moves the patient's optic nerve toward the irradiation beam that will be allowed during treatment, while still maintaining the radiation dose at the patient optic nerve below a predetermined dose level.

Claims (17)

1. A treatment planning method for treating macular degeneration in a patient, comprising:

scaling, to a measured ocular dimension of an eye, a model of the eye that includes coordinates of retinal features, including a macula and a virtual ocular medium;

establishing at least two treatment axes along which a collimated beam of X-radiation is directable from an external radiation source at the macula in the eye model;

determining, from the known distance of travel of the beam within the model along each treatment axis and from the virtual ocular medium through which the beam travels, the dose of radiation from the source that needs to be delivered along each treatment axis to produce a predetermined total radiation dose at the macula of the eye; and

directing collimated X-radiation beams at the macula in the eye.

2. The method of claim 1 , wherein scaling the model includes

measuring along an ocular axis, the ocular length of the patient's eye between the cornea and retina of the eye, and

scaling the ocular length of the model to the patient's measured ocular length.

3. The method of claim 1 , wherein establishing the at least two treatment axes includes establishing at least three treatment axes directed through the sclera and converging at the macula in the eye model, and having a total beam-to-beam angular divergence of between 20-60 degrees.

4. The method of claim 1 , wherein the eye model includes coordinates of the optic nerve at the retina, the dose of radiation is determined as specified beam intensity over a given irradiation period, and the determining the dose further includes determining a permitted extent of eye movement over the irradiation period that maintains the radiation dose received at the patient optic nerve below a predetermined level.

5. The method of claim 1 , wherein directing collimated X-radiation beams comprises producing the predetermined total radiation dose at the macula of the eye.

6. Non-transitory machine-readable medium which operates with a computer to execute machine-readable instructions for treating macular degeneration in a patient, comprising the steps of:

scaling, to a patient-eye ocular dimension supplied as input, a model of an eye that represents retinal features, including the macula and a virtual ocular medium;

establishing at least two treatment axes along which a collimated beam of X-radiation will be directed from an external radiation source at the macula in the eye model;

determining from a known distance of travel of the beam within the model along each treatment axis and from the virtual ocular medium through which the beam travels, the dose of radiation from the source that needs to be delivered along each treatment axis to produce a predetermined total radiation dose at the macula of the eye; and

directing collimated X-radiation beams at the macula in the eye.

7. The non-transitory machine-readable medium of claim 6 , wherein directing collimated X-radiation beams comprises producing the predetermined total radiation dose at the macula of the eye.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 2, 2018
From: ORAYA THERAPEUTICS, INC.
To: CARL ZEISS MEDITEC, INC.
Reel/Frame 047256/0355 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 18, 2014
From: GERTNER, MICHAEL; ARNOLDUSSEN, MARK; HANSEN, STEVEN D.; LIANG, JUNZHONG; CHELL, ERIK
To: ORAYA THERAPEUTICS, INC.
Reel/Frame 033767/0835 →
Continuity (13)
Continuation 12887419 · Sep 21, 2010
Continuation 12262031 · Oct 30, 2008
Continuation In Part 12103534 · Apr 15, 2008
Continuation In Part 12100398 · Apr 9, 2008
Continuation In Part 12027083 · Feb 6, 2008
Continuation In Part 12027094 · Feb 6, 2008
Continuation In Part 12027069 · Feb 6, 2008
Provisional Application 61101013 · Sep 29, 2008
Provisional Application 61093092 · Aug 29, 2008
Provisional Application 61076128 · Jun 26, 2008
Provisional Application 61016472 · Dec 23, 2007
Provisional Application 61020655 · Jan 11, 2008
Related Publication 20140037063A1 · Feb 6, 2014